Trial Profile
Efficacy of erlotinib at doses below maximum tolerated dose in patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Oct 2016 New trial record